French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new
French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new technetium-labeled compounds. The agreementincludes rights for a nuclear cardiology agent that shows promisein imaging myocardial ischemia and infarction, according to thecompany.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.